590 related articles for article (PubMed ID: 14982653)
1. Improving the evaluation of therapeutic interventions in multiple sclerosis: development of a patient-based measure of outcome.
Hobart JC; Riazi A; Lamping DL; Fitzpatrick R; Thompson AJ
Health Technol Assess; 2004 Mar; 8(9):iii, 1-48. PubMed ID: 14982653
[TBL] [Abstract][Full Text] [Related]
2. The Multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure.
Hobart J; Lamping D; Fitzpatrick R; Riazi A; Thompson A
Brain; 2001 May; 124(Pt 5):962-73. PubMed ID: 11335698
[TBL] [Abstract][Full Text] [Related]
3. Evidence-based measurement in multiple sclerosis: the psychometric properties of the physical and psychological dimensions of three quality of life rating scales.
Riazi A; Hobart JC; Lamping DL; Fitzpatrick R; Thompson AJ
Mult Scler; 2003 Aug; 9(4):411-9. PubMed ID: 12926848
[TBL] [Abstract][Full Text] [Related]
4. Measuring the impact of MS on walking ability: the 12-Item MS Walking Scale (MSWS-12).
Hobart JC; Riazi A; Lamping DL; Fitzpatrick R; Thompson AJ
Neurology; 2003 Jan; 60(1):31-6. PubMed ID: 12525714
[TBL] [Abstract][Full Text] [Related]
5. Multiple Sclerosis Impact Scale (MSIS-29): reliability and validity in hospital based samples.
Riazi A; Hobart JC; Lamping DL; Fitzpatrick R; Thompson AJ
J Neurol Neurosurg Psychiatry; 2002 Dec; 73(6):701-4. PubMed ID: 12438473
[TBL] [Abstract][Full Text] [Related]
6. Validity and reliability of the Finnish version of the Multiple Sclerosis Impact Scale-29.
Rosti-Otajärvi E; Hämäläinen P; Wiksten A; Hakkarainen T; Ruutiainen J
Brain Behav; 2017 Jul; 7(7):e00725. PubMed ID: 28729932
[TBL] [Abstract][Full Text] [Related]
7. Psychometric evaluation of the multiple sclerosis impact scale (MSIS-29) for proxy use.
van der Linden FA; Kragt JJ; Klein M; van der Ploeg HM; Polman CH; Uitdehaag BM
J Neurol Neurosurg Psychiatry; 2005 Dec; 76(12):1677-81. PubMed ID: 16291893
[TBL] [Abstract][Full Text] [Related]
8. Improving the evaluation of therapeutic interventions in multiple sclerosis: the role of new psychometric methods.
Hobart J; Cano S
Health Technol Assess; 2009 Feb; 13(12):iii, ix-x, 1-177. PubMed ID: 19216837
[TBL] [Abstract][Full Text] [Related]
9. Tried and tested: the psychometric properties of the multiple sclerosis impact scale (MSIS-29) in a population-based study.
Gray O; McDonnell G; Hawkins S
Mult Scler; 2009 Jan; 15(1):75-80. PubMed ID: 18829636
[TBL] [Abstract][Full Text] [Related]
10. Rasch analysis of the Multiple Sclerosis Impact Scale MSIS-29.
Ramp M; Khan F; Misajon RA; Pallant JF
Health Qual Life Outcomes; 2009 Jun; 7():58. PubMed ID: 19545445
[TBL] [Abstract][Full Text] [Related]
11. Cross-cultural adaptation and validation of the Arabic version of the Multiple Sclerosis Impact Scale-29.
Albishi AM; Alruwaili MB; Alsubiheen AM; Alnahdi AH; Alokaily AO; Algabbani MF; Alrahed Alhumaid LA; Alderaa AA; Aljarallah S
Disabil Rehabil; 2024 May; ():1-8. PubMed ID: 38738778
[TBL] [Abstract][Full Text] [Related]
12. Psychometric properties of the Croatian version of the depression, anxiety, and stress scale-21 and multiple sclerosis impact scale-29 in multiple sclerosis patients.
Rogić Vidaković M; Šimić N; Poljičanin A; Nikolić Ivanišević M; Ana J; Đogaš Z
Mult Scler Relat Disord; 2021 May; 50():102850. PubMed ID: 33636617
[TBL] [Abstract][Full Text] [Related]
13. A Quality-Adjusted Life-Year Measure for Multiple Sclerosis: Developing a Patient-Reported Health State Classification System for a Multiple Sclerosis-Specific Preference-Based Measure.
Goodwin E; Green C
Value Health; 2015 Dec; 18(8):1016-24. PubMed ID: 26686786
[TBL] [Abstract][Full Text] [Related]
14. Development and validation of a patient based measure of outcome in ocular melanoma.
Foss AJ; Lamping DL; Schroter S; Hungerford J
Br J Ophthalmol; 2000 Apr; 84(4):347-51. PubMed ID: 10729289
[TBL] [Abstract][Full Text] [Related]
15. The multiple sclerosis impact scale (MSIS-29) is a reliable and sensitive measure.
McGuigan C; Hutchinson M
J Neurol Neurosurg Psychiatry; 2004 Feb; 75(2):266-9. PubMed ID: 14742602
[TBL] [Abstract][Full Text] [Related]
16. Development of a social inclusion index to capture subjective and objective life domains (Phase II): psychometric development study.
Huxley P; Evans S; Madge S; Webber M; Burchardt T; McDaid D; Knapp M
Health Technol Assess; 2012; 16(1):iii-vii, ix-xii, -1-241. PubMed ID: 22260923
[TBL] [Abstract][Full Text] [Related]
17. Getting the measure of spasticity in multiple sclerosis: the Multiple Sclerosis Spasticity Scale (MSSS-88).
Hobart JC; Riazi A; Thompson AJ; Styles IM; Ingram W; Vickery PJ; Warner M; Fox PJ; Zajicek JP
Brain; 2006 Jan; 129(Pt 1):224-34. PubMed ID: 16280352
[TBL] [Abstract][Full Text] [Related]
18. Impact of Alzheimer's Disease on Caregiver Questionnaire: internal consistency, convergent validity, and test-retest reliability of a new measure for assessing caregiver burden.
Cole JC; Ito D; Chen YJ; Cheng R; Bolognese J; Li-McLeod J
Health Qual Life Outcomes; 2014 Sep; 12():114. PubMed ID: 25186634
[TBL] [Abstract][Full Text] [Related]
19. Psychometric properties of quality of life and health-related quality of life assessments in people with multiple sclerosis.
Learmonth YC; Hubbard EA; McAuley E; Motl RW
Qual Life Res; 2014 Sep; 23(7):2015-23. PubMed ID: 24526294
[TBL] [Abstract][Full Text] [Related]
20. Comparison of patient-reported outcome measures in multiple sclerosis.
Schäffler N; Schönberg P; Stephan J; Stellmann JP; Gold SM; Heesen C
Acta Neurol Scand; 2013 Aug; 128(2):114-21. PubMed ID: 23398571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
